Samsung Biologics Signs $262 Million Manufacturing Agreement with European Pharma Firm
Home Topics Bioprocessing Samsung Biologics Signs $262 Million Manufacturing Agreement with European Pharma Firm
Credit: Samsung Biologics
Samsung Biologics reported that it has inked a $262 million manufacturing agreement with an unnamed European pharmaceutical company. The deal includes manufacturing commitments, which will be conducted at Samsung Biologics’ Songdo manufacturing site in South Korea extending through 2033.
A Samsung Biologics’ spokesperson stated that the company’s cumulative contract value surpasses $21.9 billion following the latest agreement.
The company currently operates 845 kL of manufacturing capacity across Korea and the U.S., including 785 kL in Songdo and 60 kL at its Rockville, MD site. Acquired in March 2026, the Rockville facility established Samsung Biologics’ first manufacturing presence in the U.S., expanding the company’s global production network. Officials at Samsung Biologics say the company is also strengthening its regional presence through offices in NJ, Boston, Tokyo, and Amsterdam.
Samsung has secured land for Bio Campus III, establishing the foundation for its next phase of long-term capacity and capability expansion. The planned campus is expected to support dedicated R&D and manufacturing programs for next-generation therapeutics while the company continues to evaluate additional capacity investments in line with long-term market demand and client requirements.
Alongside capacity expansion, Samsung Biologics announced that it is pursuing opportunities to broaden its portfolio and address an increasingly diverse range of therapeutic modalities. The company has announced an all-cash offer to acquire PolyPeptide Group, which is expected to expand Samsung Biologics’ capabilities into peptide-based therapeutics and further diversify its global manufacturing network, subject to the completion of the proposed transaction.
NewsResearch and developmentTherapeuticsPolyPeptide GroupSamsung Biologics
Previous articleCancer Treatment Genetic Effects in Healthy Cells May Reveal Clues to Side Effects and Resistance
Next articleTranscenta Therapeutics and WuXi Biologics Team Up to Accelerate Commercialization of HiCB Technology
Also of Interest
Aprea Expands Development of WEE1 Inhibitor After Seeing Early Clinical Activity Signs vs. Cancer
Centrix and University of Sussex Collaborate to Drive Data-Driven Pharma Development
StockWatch: Merck/Moderna Cancer Vaccine Gives a Shot in the Arm to Sequencing Companies, Too
Next 10 U.S. Biopharma Clusters
BMS Chooses Houston for $2.3B Manufacturing Facility
StockWatch: Lilly Rises on Revenue Leap; Analysts High on Krystal Despite Revenue Miss
Related Media
AI in Protein Design: Hype vs. Reality Explained by David Baker
Celebrating DNA: Matthew Cobb's Reflections on the Double Helix
The Sun Sets on AGBT: A Report from the Last Day
Global Single-Use Network Support Assurance of Supply
Reporter's Notebook: Opening Day at the J.P. Morgan Healthcare Conference
Resins Address Downstream Purification Concerns
Top 5
Resources
Recommended For You
Podcast
--> Podcast
Touching Base
Touching Base is the dynamic podcast series from the editors of GEN.
Each episode features a rotating case of senior editors—including John Sterling, Kevin Davies, Julianna
LeMieux, Alex Phillippidis, Uduak Thomas, Corinna Singleman, and Fay Lin—who delve into emerging stories,
exchange ideas, and debate the latest trends in biotech. Additionally, they talk to some of the leading
voices in the industry about what's now and next. Start
listening today!
Stay up to date with the lasted episodes of Touching Base by subscribing to the GEN
Podcast Newsletter
